Last reviewed · How we verify
REVAXIS®
REVAXIS is a combined vaccine that provides active immunization against diphtheria, tetanus, and poliomyelitis by stimulating the immune system to produce antibodies against these three pathogens.
REVAXIS is a combined vaccine that provides active immunization against diphtheria, tetanus, and poliomyelitis by stimulating the immune system to produce antibodies against these three pathogens. Used for Booster immunization against diphtheria, tetanus, and poliomyelitis in adolescents and adults.
At a glance
| Generic name | REVAXIS® |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Inactivated combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
REVAXIS contains inactivated poliovirus antigens and toxoids of diphtheria and tetanus bacteria, which trigger adaptive immune responses without causing disease. The vaccine is administered as a booster dose to individuals who have previously received primary immunization series, restoring or maintaining protective antibody levels against these three infectious diseases.
Approved indications
- Booster immunization against diphtheria, tetanus, and poliomyelitis in adolescents and adults
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines (PHASE2, PHASE3)
- Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults (PHASE4)
- Safety of REPEVAX® Given One Month After REVAXIS® (PHASE3)
- REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children (PHASE3)
- Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis® (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- REVAXIS® CI brief — competitive landscape report
- REVAXIS® updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI